A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia.
Yan ShiHu ZhouRuibin HuangFang WangHeng MeiLie LinJingming GuoXin ZhouZhenyu LiYaorong LiuSichen LiWei ZhouYu HouMing HouPublished in: American journal of hematology (2024)
Keyphrases